What LTT Bio-Pharma does

LTT Bio-Pharma Co., Ltd. (株式会社LTTバイオファーマ) is a privately held Japanese drug discovery bio-venture founded in 1988 (spun off into its current legal form in 2003), headquartered in Tokyo with a research center at Shonan Health Innovation Park in Fujisawa. The company operates two proprietary technology platforms: Drug Repositioning (DR), supported by a proprietary library of 1,000+ approved drugs used for indication screening, and Drug Delivery System (DDS), encompassing world-first lecithinization technology (commercialized as PC-SOD), world-first stealth-type nanoparticles combining targeting and sustained release, and an established lipid emulsion DDS platform. Its marketed product family includes lipo-PGE1, lipo-NSAID, liposteroid, and transdermal steroid formulations licensed to major Japanese pharmaceutical partners and, in China, to Beijing Tide Pharmaceutical.

The company's pipeline of approximately 14 development candidates spans PC-SOD for CIPN/ARDS/myocardial infarction, LT-5001 in Phase III with Nobelpharma for trigeminal neuralgia, stealth-nanoparticle programs (Nano-PGE1, Nano-PGI2 derivative), and multiple DR-derived assets (LT-3001/3002/4001/4002/4010/4012) for COPD, dry eye, pulmonary fibrosis, and COVID-19 indications. Revenue is generated through four streams: licensing royalties and milestone payments (including from Beijing Tide for China and CKD for Korea), contract research and DR/DDS consultation services, joint development arrangements (e.g., LT-5001 with Nobelpharma; PC-SOD with Alfresa), and dividend income from the >11% equity stake in Beijing Tide Pharmaceutical. Distribution is entirely virtual: products are manufactured and commercialized by licensing partners.

LTT Bio-Pharma serves three primary customer segments: pharmaceutical companies seeking DR/DDS expertise and pipeline assets, Japanese academic institutions supported via DR Grant and PC-SOD Grant programs, and Japanese/Chinese medical companies needing cross-border licensing bridge services. The company maintains a capital and business alliance with Sino Biopharm (China's largest pharma group, 17%+ stake acquired via 2021 tender offer, renewed 2025) and operates a complex cross-shareholding with Beijing Tide Pharmaceutical (19%+ of LTT; 11%+ of Beijing Tide held by LTT). The company was listed on TSE Mothers in 2004, delisted in 2011, and is currently pursuing re-listing while reporting FY2025 net sales of ¥61.4 million against ¥5.26 billion in net assets and a 94.1% equity ratio.

Name

LTT Bio-Pharma

Legal name

株式会社LTTバイオファーマ

Website

https://ltt.co.jp

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that uses proprietary Drug Repositioning and Drug Delivery System (DDS) technologies, including a 1,000+ approved drug library and world-first lecithinization and stealth-nanoparticle platforms, to develop and out-license pipeline assets to pharmaceutical partners in Japan, China, and increasingly Europe.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Drug repositioning
• Drug delivery systems
• Pharmaceutical licensing
• Clinical drug development
• Lipid emulsion formulations

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Revenue: Revenue from licensing out pipeline assets (drug candidates at various development stages) to pharmaceutical companies. Some pipelines have progressed to Phase II clinical trials and are available for out-licensing. Also includes licensing fees from Beijing Tide Pharmaceutical for PC-SOD and AS-013 for the Chinese market, and CKD for Korean market.
2. Contract Research & Consultation: Revenue from DR (drug repositioning) screening services, intellectual property consulting, and clinical trial bridging support provided to pharmaceutical companies and academic institutions. Includes DR grants to academia with funding up to 3 million yen per project.
3. Joint Development Revenue: Revenue from joint development arrangements where the company collaborates with partners on drug development, sharing costs and profits. Notable joint development with Nobelpharma Co., Ltd. since 2018 on LT-5001, and Alfresa Holdings on PC-SOD.
4. Dividend Income: Dividend income from equity stakes in affiliated companies, primarily from Beijing Tide Pharmaceutical Co., Ltd. where LTT holds over 11% ownership.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

LTT Bio-Pharma is a Tokyo-based drug discovery bio-venture that researches, develops, and commercializes pharmaceutical products using two proprietary technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-formulated products (Lipo-PGE1, Lipo-NSAID, liposteroid, and transdermal steroid formulations) through licensing partnerships with major Japanese and Chinese pharmaceutical companies, and maintains a pipeline of 14 drug candidates in clinical and preclinical development including PC-SOD and LT-5001.

Product overview

LTT Bio-Pharma is a drug discovery bio-venture company that has developed a portfolio of pharmaceutical products utilizing two core technology platforms: Drug Repositioning (DR) and Drug Delivery Systems (DDS). The company has successfully launched multiple DDS-based formulations including lipo-PGE1 products (Palux, Riple, Kaishi), lipo-steroids (Rimetasone, Farnesone, Farenerat, Haloart), and lipo-NSAIDs (Ropion, Kaifeng). Their pipeline includes PC-SOD (lecithinized SOD1) for CIPN and other indications, stealth-type nanoparticle products (NanoPGE1, Nano PGI2), and various DR-derived candidates (LT-3001, LT-3002, LT-4001, LT-4002, LT-4010, LT-4012, LT-5001). The company operates through collaborative R&D models with academia and pharmaceutical partners, leveraging their proprietary approved drug library and DDS technologies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• PC-SOD Phase II clinical trials showed efficacy in CIPN (chemotherapy-induced peripheral neuropathy) with statistical significance
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Beijing Tide Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 10 February 2009Joint venture established in 1995 between LTT and China-Japan Friendship Hospital. LTT provides DDS technology and IP; Beijing Tide manufactures and sells DDS drugs in China. LTT holds 11%+ equity stake; Beijing Tide holds 19%+ of LTT shares. Joint R&D on PC-SOD and other pipelines. LTT acts as Beijing Tide's window for Japanese partnerships.
• Nobelpharma Co., Ltd.coreStrategic or Co-development PartnerJoint development agreement since 2018 for LT-5001 drug (drug repositioning for existing drug). Companies jointly conduct clinical trials and share profits. Nobelpharma contributes high development success rate and regulatory expertise; LTT contributes DR technology. Phase III clinical trials ongoing for trigeminal neuralgia.
• Alfresa Holdings CorporationcoreStrategic or Co-development PartnerPC-SOD joint development agreement concluded in 2025. Alfresa contributes to PC-SOD development for CIPN (chemotherapy-induced peripheral neuropathy) prevention/treatment.
• Kansai Medical UniversityminorStrategic or Co-development PartnerJoint research agreement signed April 2026 for drug discovery collaboration. Part of LTT's strategy to engage with academic institutions for pipeline development.
• Nihon University (College of Engineering)minorStrategic or Co-development PartnerContract research partner for DDS development. Collaborative research on stealth-type nanoparticle development using PLA (polylactic acid) technology.
• Musashino University (Faculty of Pharmacy)minorStrategic or Co-development PartnerCollaborative DR research for pulmonary fibrosis treatment. Jointly screened approved drug library with LTT to discover LT-4010 for idiopathic pulmonary fibrosis.
• Shujitsu University (Faculty of Pharmacy)minorStrategic or Co-development PartnerContract research partner for drug development activities.
• Aska Pharmaceutical Holdings Co., Ltd.minorOthersDR consulting service agreement concluded 2021 for drug repositioning expertise and guidance.
• ChongKunDang Pharm Corp (CKD)minorOEM/ Whitelabel/ Licensing PartnerLicensed PC-SOD (inhalation formulation) for entire Korean territory in 2011.
• EA Pharma Co., Ltd.minorOEM/ Whitelabel/ Licensing PartnerLicense agreement signed 2015 for pipeline LT-4004.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• NanoCarrier: Japanese bio-venture specializing in micellar nanoparticle drug delivery technology for nucleic acid drugs and other therapeutics. Direct comparable as a small-cap Japanese DDS-focused biotech with similar licensing model.
• SymBio Pharmaceuticals: Japanese specialty pharmaceutical company focused on niche therapeutic areas with in-licensing and co-development model. Similar size and venture-stage profile with comparable revenue/development stage.
• AnGes: Japanese bio-venture developing novel biologics and gene therapies, with similar late-stage clinical assets and licensing-driven business model. Comparable venture-stage bio-pharma with multiple pipeline candidates.

Broad incumbents

• JCR Pharmaceuticals: Japanese biopharmaceutical company with proprietary drug delivery technologies including J-Brain Cargo platform for CNS drug delivery. Larger established player with overlapping DDS expertise but broader portfolio.
• Mochida Pharmaceutical: Japanese specialty pharmaceutical company with focus on specialty pharma, regenerative medicine, and novel drug formulations. Larger incumbent with overlap in specialty pharmaceutical development.
• Takeda Pharmaceutical: Japan's largest pharmaceutical company and LTT's landlord through Shonan iPark affiliation. Established incumbent with DDS interest and partnership potential as a licensee for LTT's pipeline assets.

Emerging players

• PeptiDream: Japanese bio-pharma with proprietary peptide discovery platform serving global pharma partners via licensing deals. Similar platform-based business model with global pharma licensing as core revenue driver.
• Sosei Group Corporation: Japanese biotech with proprietary drug discovery platform (StaR/SBDD) generating licensing revenue from global pharma partners. Similar platform-tech licensing model with comparable Japan listing history.

Others

• EPS Holdings: Japanese CRO and pharma services provider. Not a direct competitor but comparable as a Japan-listed pharma services/development company serving similar pharmaceutical customers.
• CMIC Holdings: Japan's largest CRO providing drug development services including clinical trial support. Comparable as Japanese pharma services/development ecosystem participant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LTT Bio-Pharma